Merck has commenced the P-III clinical evaluation of MK-1084 + Keytruda vs Keytruda + PBO in treatment-naïve KRAS G12C-mutated metastatic NSCLC patients (n=600) having PD-L1 TPS ≥50% with 1EPs as PFS & OS as well as 2EPs include ORR & DoR
The company is assessing MK-1084 alone and in combinations under the ongoing P-I study for its safety, efficacy, tolerability & PK characteristics for the treatment of advanced solid tumors associated with KRAS G12C mutations. The data was highlighted at the ESMO 2023
MK-1084 is a potent and specific covalent inhibitor of KRAS G12C, the mutations of which are commonly observed in non-small cell lung cancer, pancreatic, urogenital and colorectal cancers
Ref: Merck | Image: Merck
Related News:- Pfizer’s Braftovi (encorafenib) + Mektovi (binimetinib) Receives the US FDA’s Approval for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
